ALCAM and breast carcinoma: Previous investigations have demonstrated an upregulation of CD166 in breast cancer cases, highlighting a notable distinction in serum CD166 expression between breast cancer patients and healthy volunteers and concluded CD166 diagnostic accuracy [10-16].